From GlobeNewswire: 2025-03-24 00:01:00

Opthea’s Phase 3 COAST trial for wet AMD did not meet the primary endpoint of mean change in BCVA from baseline to week 52. Participants on sozinibercept combination therapy did not show significant improvement compared to aflibercept monotherapy. Opthea is reviewing the data but has concerns about its financial obligations under the Development Funding Agreement, potentially impacting the company’s solvency. Opthea is in discussions with investors to find a resolution. With uncertainty about its ability to continue as a going concern, trading in Opthea’s securities remains suspended until more clarity is provided. Opthea has extended its voluntary suspension and emphasizes the inherent risks of investing in biotechnology companies, urging caution and professional advice. The company acknowledges uncertainties in drug development, patent protection, regulatory approvals, and market trends. Opthea’s forward-looking statements caution against relying on projections, as actual results may vary due to multiple variables beyond their control. Investors are advised to review Opthea’s financial statements for additional information. For inquiries, contact PJ Kelleher at LifeSci Advisors, LLC. Stay updated by joining Opthea’s email database. Opthea Limited remains committed to transparency and investor communication.



Read more at GlobeNewswire: Opthea Announces COAST Phase 3 Trial Topline Results